Denosumab is a long-term option for the management of parathyroid carcinoma-related refractory hypercalcemia.

Fountas, A

Denosumab is a long-term option for the management of parathyroid carcinoma-related refractory hypercalcemia. [electronic resource] - QJM : monthly journal of the Association of Physicians 01 2017 - 53-54 p. digital

Publication Type: Letter; Comment

1460-2393

10.1093/qjmed/hcw206 doi


Antibodies, Monoclonal, Humanized
Denosumab
Humans
Hypercalcemia
Paraneoplastic Syndromes
Parathyroid Hormone
Parathyroid Neoplasms